James T. McCracken, MD

  • 7Articles
  • 22.4KReads1
  • 2002–2022Active
  • 38Collaborators
  • 177Citations2

1 Read counts for articles published before 2020 may include some non-human traffic.

2 Citation counts provided by Crossref.

About

James T. McCracken, MD, is affiliated with the University of California, Los Angeles (UCLA) Semel Institute for Neuroscience and Human Behavior. His publications from 2002 to 2022 focus on anxiety, child and adolescent psychiatry, psychotherapy, anxiolytics, depression, neurodevelopmental disorders, and schizophrenia/schizoaffective disorders. His work includes studies on pharmacotherapy initiation following cognitive-behavioral therapy in anxious youth, long-term outcomes of adolescent depression, and safety issues with drug therapies for autism spectrum disorders.

Publications

JCP
Pharmacotherapy After CBT in Anxious Youth
Original Research

Pharmacotherapy After CBT in Anxious Youth

December 5, 2022

This study of youth with anxiety disorders compared cognitive-behavioral therapy (CBT) non-remitters who initiated pharmacotherapy to those who did not and sought to identify predictors of the decision to...
, , , et al
JCP
Correction

Correction: Long-Term Outcome of Adolescent Depression

October 23, 2019

, , , et al
JCP
Meta-Analysis

d-Cycloserine in Exposure Therapy

February 22, 2017

While exposure-based cognitive-behavioral therapy is effective for anxiety disorders, many patients often experience inadequate results from this treatment. This meta-analysis examines whether d-Cycloserine as an adjunct to CBT might...
, , , et al
JCP
Original Research

Iron Homeostasis During Risperidone Treatment in Children and Adolescents

August 4, 2015

, , , et al
JCP
Article

Long-Term Outcome of Adolescent Depression Initially Resistant to Selective Serotonin Reuptake Inhibitor Treatment: A Follow-Up Study of the TORDIA Sample

November 16, 2010

, , , et al
JCP
Article

Safety Issues With Drug Therapies for Autism Spectrum Disorders.

December 15, 2005

JCP
Article

Childhood and Early-Onset Anxiety: Treatment and Biomarker Studies

June 1, 2002

, ,

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Ketamine and Psychedelics

Listen to the Podcast
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe